XFOR

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a late-stage clinical biopharmaceutical company founded in 2010 and headquartered in Boston, Massachusetts. The company went public in November 2017 and focuses on developing novel therapeutics for rare diseases. X4 Pharmaceuticals achieved a significant milestone in 2024 with the FDA approval and commercial launch of its lead drug XOLREMDI (mavorixafor) for WHIM syndrome, marking its transition from a pure development-stage company to a commercial-stage biopharmaceutical enterprise.